CYTK
Price
$67.68
Change
-$6.30 (-8.52%)
Updated
Mar 4, 6:59 PM EST
59 days until earnings call
MDGL
Price
$247.15
Change
-$4.48 (-1.78%)
Updated
Mar 4, 3:27 PM EST
64 days until earnings call
Ad is loading...

Compare trend and price CYTK vs MDGL

Header iconCYTK vs MDGL Comparison
Open Charts CYTK vs MDGLBanner chart's image
Cytokinetics
Price$67.68
Change-$6.30 (-8.52%)
Volume$2.22M
CapitalizationN/A
Madrigal Pharmaceuticals
Price$247.15
Change-$4.48 (-1.78%)
Volume$200
CapitalizationN/A
View a ticker or compare two or three
CYTK vs MDGL Comparison Chart

Loading...

CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CYTK vs. MDGL commentary
Mar 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and MDGL is a Buy.

COMPARISON
Comparison
Mar 04, 2024
Stock price -- (CYTK: $73.98 vs. MDGL: $251.63)
Brand notoriety: CYTK and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 33% vs. MDGL: 97%
Market capitalization -- CYTK: $7.25B vs. MDGL: $5.01B
CYTK [@Biotechnology] is valued at $7.25B. MDGL’s [@Biotechnology] market capitalization is $5.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $550.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 2 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 2 green, 3 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 3 TA indicator(s) are bullish while MDGL’s TA Score has 7 bullish TA indicator(s).

  • CYTK’s TA Score: 3 bullish, 5 bearish.
  • MDGL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -5.18% price change this week, while MDGL (@Biotechnology) price change was +6.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.19%. For the same industry, the average monthly price growth was +19.18%, and the average quarterly price growth was +53.54%.

Reported Earning Dates

CYTK is expected to report earnings on May 02, 2024.

MDGL is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+4.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($7.25B) has a higher market cap than MDGL($5.01B). MDGL YTD gains are higher at: 8.752 vs. CYTK (-11.391). MDGL has higher annual earnings (EBITDA): -360.39M vs. CYTK (-462.64M). MDGL has more cash in the bank: 634M vs. CYTK (539M). MDGL has less debt than CYTK: MDGL (117M) vs CYTK (748M). CYTK has higher revenues than MDGL: CYTK (7.82M) vs MDGL (0).
CYTKMDGLCYTK / MDGL
Capitalization7.25B5.01B145%
EBITDA-462.64M-360.39M128%
Gain YTD-11.3918.752-130%
P/E RatioN/AN/A-
Revenue7.82M0-
Total Cash539M634M85%
Total Debt748M117M639%
FUNDAMENTALS RATINGS
CYTK vs MDGL: Fundamental Ratings
CYTK
MDGL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
1240
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3541
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (12) in the Biotechnology industry is in the same range as MDGL (40) in the Pharmaceuticals Other industry. This means that CYTK’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CYTK (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (35) in the Biotechnology industry is in the same range as MDGL (41) in the Pharmaceuticals Other industry. This means that CYTK’s stock grew similarly to MDGL’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CYTK’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKMDGL
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
77%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
78%
View a ticker or compare two or three
Ad is loading...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RULE21.920.48
+2.24%
Adaptive Core ETF
AFLG29.890.25
+0.84%
First Trust Active Factor Large Cap ETF
EVN10.200.05
+0.49%
Eaton Vance Municipal Income Trust
FAAR28.450.11
+0.39%
First Trust Alt Abs Ret Strat ETF
TOTL39.710.11
+0.28%
SPDR® DoubleLine Total Return Tact ETF

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with IBRX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then IBRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+6.53%
IBRX - MDGL
62%
Loosely correlated
-0.42%
KA - MDGL
62%
Loosely correlated
+8.66%
VXRT - MDGL
61%
Loosely correlated
+2.46%
SRNEQ - MDGL
58%
Loosely correlated
-25.93%
RLAY - MDGL
57%
Loosely correlated
+0.60%
More